What does this research mean for the field?

In real-world settings, asciminib demonstrates favorable clinical efficacy, including high major molecular response rates, and a manageable safety profile in pre-treated patients with chronic phase chronic myeloid leukemia. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

What question did this study set out to answer?

To evaluate the real-world clinical efficacy and safety of asciminib in patients with chronic myeloid leukemia in chronic phase who have received two or more prior lines of therapy.

August 22, 2026BMC CancerOpen Access

Clinical efficacy and safety of asciminib in chronic myeloid leukemia-chronic phase (CML-CP) in real-world settings: a systematic literature review

View Full Paper

Ask AI

Bookmark

Authors

NKNitin KaushikGovernment General Hospital GGGreeshma GopalanNovartis (India)AMAlessandra MistoNovartis (France)

Discussion

Member takes

Implication

Systematic review reveals favorable molecular responses and manageable toxicity with asciminib in pretreated chronic myeloid leukemia, highlighting its clinical utility in real-world practice.

Key Points

To evaluate the real-world clinical efficacy and safety of asciminib in patients with chronic myeloid leukemia in chronic phase who have received two or more prior lines of therapy.
Conducted a systematic literature review searching Embase, MEDLINE, and Cochrane databases for real-world evidence.
Identified and synthesized data from 22 studies with sample sizes ranging from 12 to 394 patients.
Complete cytogenetic response rates ranged from 8% to 73%, and major molecular response (MMR) rates ranged from 17% to 67% (65% in ponatinib-naïve vs. 10% in ponatinib-pretreated patients; up to 80% in TKI-intolerant patients).
Overall survival ranged from 73% to 100% across studies, with gradual MMR improvements noted over time in patients with T315I mutations.
Adverse events were manageable, most frequently presenting as thrombocytopenia, fatigue, and rash, with treatment discontinuations due to adverse events occurring in ≤ 16% of patients.

Cite This Study

Kaushik et al. (2026) studied this question.

synapsesocial.com/papers/6a895f41ca7ade938187db25 https://doi.org/10.1186/s12885-026-16775-9

View Full Paper

Ask AI

Bookmark

Implication

Systematic review reveals favorable molecular responses and manageable toxicity with asciminib in pretreated chronic myeloid leukemia, highlighting its clinical utility in real-world practice.

Clinical efficacy and safety of asciminib in chronic myeloid leukemia-chronic phase (CML-CP) in real-world settings: a systematic literature review

Discussion

Member takes

Implication

Key Points

Cite This Study

Clinical efficacy and safety of asciminib in chronic myeloid leukemia-chronic phase (CML-CP) in real-world settings: a systematic literature review

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider